Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R B Rothman

Showing results (191-200 of 262) with videos related to

Pageof 27
Sort By:
European Journal of Pharmacology|May 13, 1986
Morphine tolerance increases mu-noncompetitive delta binding sitesR B Rothman, J A Danks, A E Jacobson, et al.
Synapse (New York, N.Y.)|November 9, 2000
Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [(35)S]GTP-gamma-S functional binding assayH Xu, A Hashimoto, K C Rice, et al.
European Journal of Pharmacology|August 29, 1989
Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypesR B Rothman, C P France, V Bykov, et al.
NIDA Research Monograph|January 1, 1989
In vivo binding of (+)-cis methylfentanyl at the opiate receptor complex and behavioral correlates: evidence for a novel mechanism of actionL Band, V Bykov, N Greig, et al.
Synapse (New York, N.Y.)|September 29, 1999
Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assayD V Romero, J S Partilla, Q X Zheng, et al.
Peptides|January 8, 1999
Regulation of mu binding sites after chronic administration of antibodies directed against specific anti-opiate peptidesC B Goodman, S Heyliger, B Emilien, et al.
Psychopharmacology|September 1, 1996
Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaineJ K Staley, Q Ouyang, J Pablo, et al.
NIDA Research Monograph|January 1, 1991
Preliminary evidence that the high affinity dopamine reuptake inhibitor, GBR12909, antagonizes the ability of cocaine to elevate extracellular levels of dopamineR B Rothman, A Mele, A A Reid, et al.
Peptides|March 4, 2000
Chronic exposure to antibodies directed against anti-opiate peptides alter delta-opioid receptor levelsC B Goodman, S Heyliger, B Emilien, et al.
Life Sciences|January 1, 1990
The potent opioid agonist, (+)-cis-3-methylfentanyl binds pseudoirreversibly to the opioid receptor complex in vitro and in vivo: evidence for a novel mechanism of actionL Band, H Xu, V Bykov, et al.
Pageof 27

Showing results (191-200 of 262) with videos related to

Sort By:
Pageof 27
European Journal of Pharmacology|May 13, 1986
Morphine tolerance increases mu-noncompetitive delta binding sitesR B Rothman, J A Danks, A E Jacobson, et al.
Synapse (New York, N.Y.)|November 9, 2000
Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [(35)S]GTP-gamma-S functional binding assayH Xu, A Hashimoto, K C Rice, et al.
European Journal of Pharmacology|August 29, 1989
Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypesR B Rothman, C P France, V Bykov, et al.
NIDA Research Monograph|January 1, 1989
In vivo binding of (+)-cis methylfentanyl at the opiate receptor complex and behavioral correlates: evidence for a novel mechanism of actionL Band, V Bykov, N Greig, et al.
Synapse (New York, N.Y.)|September 29, 1999
Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assayD V Romero, J S Partilla, Q X Zheng, et al.
Peptides|January 8, 1999
Regulation of mu binding sites after chronic administration of antibodies directed against specific anti-opiate peptidesC B Goodman, S Heyliger, B Emilien, et al.
Psychopharmacology|September 1, 1996
Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaineJ K Staley, Q Ouyang, J Pablo, et al.
NIDA Research Monograph|January 1, 1991
Preliminary evidence that the high affinity dopamine reuptake inhibitor, GBR12909, antagonizes the ability of cocaine to elevate extracellular levels of dopamineR B Rothman, A Mele, A A Reid, et al.
Peptides|March 4, 2000
Chronic exposure to antibodies directed against anti-opiate peptides alter delta-opioid receptor levelsC B Goodman, S Heyliger, B Emilien, et al.
Life Sciences|January 1, 1990
The potent opioid agonist, (+)-cis-3-methylfentanyl binds pseudoirreversibly to the opioid receptor complex in vitro and in vivo: evidence for a novel mechanism of actionL Band, H Xu, V Bykov, et al.
Pageof 27